Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2013-10-15 Annual Report
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
ANNUAL REPORT
Annual Report FY 2013
2013-10-15 English
LATE FILING NOTICE
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company is unable to file its Form 10-K on time and is requesting additional time to file it. The document does not contain the actual 10-K report or any financial data, but rather is a regulatory notice about the delay in filing the 10-K. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing, not the report itself.
2013-09-26 English
Major Shareholding Notification 2013
Major Shareholding Notification
2013-08-02 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2013
2013-05-20 English
NOTICE OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company is unable to file its Form 10-Q quarterly report on time and requests an extension. The document does not contain actual financial data or the report itself but is an announcement regarding the delay in filing the quarterly report. The document length is 4364 characters, which is relatively short and consistent with a notification form rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing rather than the financial report itself.
2013-05-15 English
Regulatory Filings 2013
Regulatory Filings
2013-05-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.